Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
Michel Delforge, Evangelos Terpos, Paul G. Richardson, Ofer Shpilberg, Nuriet K. Khuageva, Rudolf Schlag, Meletios A. Dimopoulos, Martin Kropff, Ivan Spicka, Maria T. Petrucci, Olga S. Samoilova, Maria Victoria Mateos, Hila Magen-Nativ, Hartmut Goldschmidt, Dixie Lee Esseltine, Deborah S. Ricci, Kevin Liu, William Deraedt, Andrew Cakana, Helgi Van de VeldeJesús F. San Miguel
Research output: Contribution to journal › Article › peer-review
71Scopus
citations
Fingerprint
Dive into the research topics of 'Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma'. Together they form a unique fingerprint.